J. Omongin

Microbial Translocation Does Not Drive Immune Activation in Ugandan Children Infected With HIV

N. Klein, F. Fitzgerald, A. Sarah Walker, 2019 .

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial

P. Easterbrook, H. Namata, A. Siika, 2018, The Lancet. Infectious diseases.

Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial

P. Easterbrook, T. Peto, N. French, 2017, The lancet. HIV.

Effect of ready-to-use supplementary food on mortality in severely immunocompromised HIV-infected individuals in Africa initiating antiretroviral therapy (REALITY): an open-label, parallel-group, randomised controlled trial

J. Seeley, A. Shali, A. Walker, 2018, The lancet. HIV.

Late Presentation With HIV in Africa: Phenotypes, Risk, and Risk Stratification in the REALITY Trial

J. Seeley, K. Maitland, A. Shali, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy in Low-income Countries: An Observational Analysis Within the EARNEST Randomized Trial

P. Easterbrook, N. French, H. Namata, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Microbial Translocation Does Not Drive Immune Activation in Ugandan Children Infected With HIV

F. Fitzgerald, A. Sarah Walker, V. Mulenga, 2018, The Journal of infectious diseases.